The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
November 20th 2024
Bimekizumab-bkzx is the first and only approved medication that targets both interleukin (IL) 17F and IL-17A.
November 13th 2024
More Than Half of American Adults with Multiple Sclerosis Report Mistreatment by Caregivers
February 10th 2021Patients with multiple sclerosis who rely on family members as caregivers may be at particular risk for mistreatment, as those caregivers struggle to balance work, childcare, and health concerns of their own.
Read More
FDA Grants Breakthrough Therapy Designations for Investigational STAMP inhibitor in CML
February 9th 2021The BTD designations for asciminib were based on the phase 3, multicenter, open-label, randomized ASCEMBL trial and a phase I trial that included patients with Ph+ CML, some of them harboring the T315I mutation.
Read More
FDA Approves Breyanzi for Adults with Relapsed, Refractory Large B-cell Lymphoma
February 8th 2021Of 192 study participants who received Breyanzi, 73% achieved a response, including 54% who had minimal or no detectable lymphoma remaining following treatment and 19% who achieved a partial response.
Read More
FDA Grants Accelerated Approval to Treatment for Marginal Zone Lymphoma, Follicular Lymphoma
February 8th 2021The FDA has granted an accelerated approval to umbralisib for the treatment of select patients with relapsed/refractory marginal zone lymphoma and relapsed/refractory follicular lymphoma.
Read More
Study Finds Oral Azacitidine as AML Maintenance Treatment Prolongs Survival
February 3rd 2021Patients with AML that has gone into remission following initial chemotherapy were found to remain in remission longer and have improved OS if they took a pill form of azacitidine as a maintenance treatment.
Read More
First Mammography Screening Guidelines Issued for Older Survivors of Breast Cancer
February 2nd 2021The guidelines recommend discontinuing routine mammograms for survivors with a life expectancy under 5 years, considering stopping screening for those with a 5- to 10-year life expectancy, and continuing mammography for those whose life expectancy is greater than 10 years.
Read More
Study: Male Breast Cancer Patients Have High Prevalence of Heart Disease Risk Factors
February 1st 2021Research highlights the need for cardiologists and cardio-oncologists to be involved in the treatment of men with breast cancer due to common risk factors and potential cardiotoxic effects of treatment.
Read More
Biologics License Application for Bevacizumab Biosimilar BAT1706
January 29th 2021If approved, the biosimilar will be indicated for use in metastatic colorectal cancer, nonsquamous non–small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, and metastatic cervical cancer.
Read More
Association of Community Cancer Centers Releases Latest Podcast that Offers Tips for Onco-Pharmacy
January 26th 2021Topics covered in-depth in the show include strategies for patient education, cancer team coordination, side effect monitoring and management of medications from both in-house and external specialty pharmacies.
Read More
Triggering a Tumor Antiviral Immune Response in Patients With Triple-Negative Breast Cancer
January 22nd 2021During a study investigating therapeutics that target how RNA splicing activates antiviral immune pathways in triple-negative breast cancers, researchers observed that endogenous RNA in tumor cells that had been mis-spliced is able to mimic an RNA virus.
Read More
Study: Sharp Decline in Cancer Screenings, Diagnoses During the First COVID-19 Surge
January 21st 2021The study findings emphasize the need for people who missed or postponed a cancer screening test early in the pandemic to contact their health care provider to discuss the potential need to reschedule it, according to the study authors.
Read More
FDA Grants Priority Review to Treatment for Resected Esophageal or Gastroesophageal Junction Cancer
January 21st 2021FDA grant priority review to a supplemental biologics license application for nivolumab (Opdivo) for use as an adjuvant treatment for patients with resected esophageal or gastroesophageal junction cancer.
Read More